Literature DB >> 30755146

Complete renal response at 12 months after induction therapy is associated with renal relapse-free rate in lupus nephritis: a single-center, retrospective cohort study.

K Ichinose1, M Kitamura2, S Sato3, M Eguchi1, M Okamoto1, Y Endo1, S Tsuji1, A Takatani1, T Shimizu1, M Umeda1, S Fukui1, R Sumiyoshi1, T Koga1, S Kawashiri1, N Iwamoto1, T Igawa1, M Tamai1, H Nakamura1, T Origuchi4, T Nishino2, A Kawakami1.   

Abstract

BACKGROUND: Lupus nephritis (LN) is a major risk factor for overall morbidity and mortality in systemic lupus erythematosus (SLE).
METHODS: We retrospectively analyzed cases of proliferative and membranous LN patients who underwent a renal biopsy at our hospital in 1993-2016. We analyzed the association between complete renal response (CR) rates at 12 months after induction therapy and predictive factors for CR and their association with renal flares.
RESULTS: Of the 95 cases analyzed, we were able to track the therapeutic responses of 81 patients at 12 months after their induction therapy. The median follow-up duration after renal biopsy was 51 months (interquartile range: 16.5-154.5 months). The Cox proportional hazards model showed that, compared to not attaining CR at 12 months, the attainment of CR at 12 months was correlated with being free from renal flares. The multivariate logistic analysis revealed that the predictive factors for CR at 12 months were the anti-La/SSB antibodies (U/ml) (odds ratio (OR) 1.22, 95% confidence interval (CI) 1.01-1.63, p = 0.0220), blood urea nitrogen (BUN) (OR 0.68, 95% CI 0.44-0.90, p = 0.00048) and serum β2 microglobulin (MG) (OR 0.26, 95% CI 0.06-0.74, p = 0.00098) levels.
CONCLUSIONS: Among LN patients, being free from renal flares was associated with attaining CR at 12 months after induction therapy. Anti-La/SSB antibodies were a positive predictive factor, and BUN and serum β2MG levels were negative predictive factors of CR at 12 months.

Entities:  

Keywords:  Anti-La/SSB antibodies; complete renal response; proliferative and membranous lupus nephritis; serum β2 microglobulin

Mesh:

Substances:

Year:  2019        PMID: 30755146     DOI: 10.1177/0961203319829827

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  5 in total

Review 1.  Lupus Nephritis: Improving Treatment Options.

Authors:  Myrto Kostopoulou; Sofia Pitsigavdaki; George Bertsias
Journal:  Drugs       Date:  2022-04-29       Impact factor: 9.546

2.  Differences and similarities of proliferative and non-proliferative forms of biopsy-proven lupus nephritis: Single centre, cross-disciplinary experience.

Authors:  Emine Duran; Tolga Yıldırım; Arzu Taghiyeva; Emre Bilgin; Mustafa Arıcı; Emine Arzu Sağlam; Seza Özen; Meral Üner; Yunus Erdem; Umut Kalyoncu; Ali Ihsan Ertenli
Journal:  Lupus       Date:  2022-06-03       Impact factor: 2.858

3.  Predictors of Early Response, Flares, and Long-Term Adverse Renal Outcomes in Proliferative Lupus Nephritis: A 100-Month Median Follow-Up of an Inception Cohort.

Authors:  Eleni Kapsia; Smaragdi Marinaki; Ioannis Michelakis; George Liapis; Petros P Sfikakis; John Boletis; Maria G Tektonidou
Journal:  J Clin Med       Date:  2022-08-26       Impact factor: 4.964

4.  Comparison of complete renal response and mortality in early- and late-onset lupus nephritis: a multicenter retrospective study of a Japanese cohort.

Authors:  Kunihiro Ichinose; Mineaki Kitamura; Shuntaro Sato; Keita Fujikawa; Yoshiro Horai; Naoki Matsuoka; Masahiko Tsuboi; Fumiaki Nonaka; Toshimasa Shimizu; Remi Sumiyoshi; Tomohiro Koga; Shin-Ya Kawashiri; Naoki Iwamoto; Takashi Igawa; Mami Tamai; Hideki Nakamura; Tomoki Origuchi; Tomoya Nishino; Atsushi Kawakami
Journal:  Arthritis Res Ther       Date:  2020-07-22       Impact factor: 5.156

5.  Outcomes of membranous and proliferative lupus nephritis - analysis of a single-centre cohort with more than 30 years of follow-up.

Authors:  Filipa Farinha; Ruth J Pepper; Daniel G Oliveira; Thomas McDonnell; David A Isenberg; Anisur Rahman
Journal:  Rheumatology (Oxford)       Date:  2020-11-01       Impact factor: 7.046

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.